tldrdailynews.com logo

Novartis trims pipeline and boosts outlook.

1 min read
Source: Endpoints News
Novartis trims pipeline and boosts outlook.
Photo: Endpoints News
TL;DR Summary

Novartis is cutting around 10% of its pipeline after a comprehensive review of R&D projects during Q1 2023. The Swiss company will discontinue or out-license projects based on considerations like strategic fit, asset value, commercial potential, and competitive landscape. The move is part of CEO Vas Narasimhan's campaign to turn Novartis into a "pure-play" drugmaker.

Topics:business#discontinuation#drug-development#novartis#pharmaceutical-industry#pipeline#randd
Share this article
  1. Novartis cuts 10% of pipeline after R&D review – Endpoints News  Endpoints News
  2. Novartis prunes assets, axing 10% of pipeline programs to narrow R&D focus  FierceBiotech
  3. Novartis' Kisqali, Pluvicto top list of investor concerns  FiercePharma
  4. Pharmalittle: Novartis boosts its sales and profit outlook; Biogen trims its drug pipeline  STAT
  5. Novartis, helped by cost cuts, raises full-year outlook  Yahoo Finance

Reading Insights

Total Reads

0

Unique Readers

22

Time Saved

7 min

vs 7 min read

Condensed

96%

1,400 → 55 words

Want the full story? Read the original article

Read on Endpoints News